• Mashup Score: 2

    Formerly known as nonalcoholic fatty liver disease, the condition will now be known as metabolic dysfunction-associated steatotic liver disease.

    Tweet Tweets with this article
    • 🤔 How long does it take a new medical term to catch on? ❌ Goodbye ‘fatty liver disease’ (& stigma) 📚 New term: MASLD (metabolic dysfunction-associated steatotic liver disease). A Liver Disease Gets a New Name, Diagnostic Criteria https://t.co/1fuUuWYQRY @Medscape

  • Mashup Score: 7

    The ATA Women in Thyroidology group invites you to join the webinar. The Pathway to Transformational Leadership Moderators: Toni Beninato, MD and Rachel Pessah-Pollack, MD  Panelists: Nancy Carrasco, MD – ATA Women in Thyroidology Member Jacqueline Jonklaas, MD, PhD – ATA Secretary Amanda Perl – ATA Executive Director Julie Ann Sosa, MD, MSc – ATA President  Time Zone The time listed below…

    Tweet Tweets with this article
    • Excited to moderate this all-star panel with @BeninatoToni on Aug. 3rd - an incredible team of #WomenInThyroidology leaders. Register now 👇🏼👇🏼👇🏼 https://t.co/9b0wWvlcYy @AmThyroidAssn @MariaPapaleont1 @CarrieEPrewitt @amandaperl @Jasosamd @AngelaLeung9 @nyuendocrine #EndoTwitter https://t.co/A7pYffMC47

  • Mashup Score: 1

    Demand for Ozempic continues to surge, fueled by social media; but research suggests that for some, use of these injectables may be linked to increased risk for thyroid cancer.

    Tweet Tweets with this article
    • Enjoyed sharing my perspective on this hot (& timely) topic: TikTok's Fave #WeightLoss Drugs: Link to Thyroid Cancer? https://t.co/kULAZiBRlJ via @medscape. @AmThyroidAssn #ozempic #EndoTwitter

  • Mashup Score: 2

    Listen to this episode from Honestly with Bari Weiss on Spotify. Ozempic, the brand name drug for a medication called semaglutide, is one of the most popular drugs on the market right now. Originally developed to treat type 2 diabetes, the injectable drug has recently boomed in popularity for its off-label use to help people lose weight… fast. Celebrities and public figures have admitted…

    Tweet Tweets with this article
    • Must-listen to #podcast by @bariweiss highlighting #obesity as a disease & helping patients with #weightloss. 👏🏻👏🏻👏🏻 to @Chikagirl & @VPrasadMDMPH for sharing accurate medical information #EndoTwitter https://t.co/oGCDghXos1

  • Mashup Score: 0

    Few older adults who undergo total thyroidectomy for treatment of Graves’ disease developed hypoparathyroidism requiring calcitriol therapy, according to data published in Thyroid. “Operative management with total thyroidectomy will not be the best option for all older adults with Graves’ disease, some of whom may have increased surgical risk due to other medical

    Tweet Tweets with this article
    • Enjoyed sharing my perspective on this @AmThyroidAssn study finding a low rate of hypoparathyroidism after #thyroid surgery for Graves' disease in older adults @healio @EndocrineToday #EndoTwitter https://t.co/gI5uDNJvrY

  • Mashup Score: 3

    The FDA has approved abaloparatide, a parathyroid hormone-related peptide analog, to increase bone mineral density among men with osteoporosis at high risk for fracture, according to an industry press release. Abaloparatide (Tymlos, Radius Health) was approved based on the findings from the phase 3 Abaloparatide Treatment for Men (ATOM) study. As Healio previously reported at the 2022 AACE

    Tweet Tweets with this article
    • At last: another #osteoporosis med FDA approved for MEN ✅. Abaloparatide for high fracture risk 🙋🏻‍♂️@GoHealio @Densitometry @ASBMR @TheAACE @TheEndoSociety https://t.co/t09d9xnr0J

  • Mashup Score: 1

    SAN DIEGO — Adolescents with obesity had a BMI reduction of 16.1% at 68 weeks with once-weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention, results similar to those seen with adults, according to top-line results presented at ObesityWeek 2022. In findings from the STEP TEENS phase 3a trial, adolescents aged 12 to 17 years with obesity or overweight and at least one

    Tweet Tweets with this article
    • Incredible weight loss in adolescents with obesity with semaglutide (16% BMI ⬇️ at 68 weeks). @GoHealio #teens #health #EndoTwitter https://t.co/QOjnC1wZUD